제품 > 항체 > Biosimilar Antibody

Human CD30 Monoclonal Antibody (YR0005)

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human TNFRSF8 /CD30 (Research Grade Brentuximab Biosimilar) Monoclonal Antibody to TNFRSF8 /CD30. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

Human CD30 SPR assay. Determined through SPR assay, the Human Anti-Human CD30 (Research Grade Brentuximab Biosimilar) Monoclonal Antibody is capable of binding to Human CD30 with an affinity constant of 3.719 nM.

ABclonal:Flow CytoMetry - Human CD30 Monoclonal Antibody (YR0005)

Detection of CD30 in K562 cell line by Flow Cytometry. K562 cell line was stained with Human Anti-Human CD30 (Brentuximab Biosimilar) Monoclonal Antibody followed by APC conjugated Anti-Human IgG Secondary Antibody, or unstained cells (open blue histogram).

Basic Information

Clone	Brentuximab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Target Background

Brentuximab is a biosimilar directed against the extracellular domain of CD30. The brentuximab antibody selectively targets tumor cells expressing the cell membrane protein CD30 and delivers the MMAE, which causes apoptosis by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtuble network, thereby preventing tumor growth and proliferation.